Introduction to 3 Double Blind

What is/are 3 Double Blind?

3 Double Blind - A phase 3 double-blind trial showed that brexanolone was no better than placebo for successful wean of 3rd line anesthetic agent(s) and freedom from RSE for ≥24 hours. ^[1] Methods The Safety of Urate Elevation in Parkinson’s Disease (SURE-PD) trial enrolled 75 people with early PD and baseline serum urate below 6 mg/dL and randomized them to 3 double-blinded treatment arms: oral placebo or inosine titrated to produce mild (6. ^[2] In this report, Scully et al present the findings from an international phase 3 double-blind, randomized, placebo-controlled trial (HERCULES) investigating the safety and efficacy of caplacizumab in patients with acquired TTP. ^[3] This method was verified by 13 double-blinded gelatin samples, all the 13 samples were accurately identified. ^[4] Methods SAMURAI and SPARTAN were Phase 3 double-blind studies of patients with migraine, randomized to oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo to be taken within 4 hours of onset of migraine pain. ^[5] , Cambridge, MA, UNC School of Medicine, Chapel Hill, NC, Atlanta Center for Medical Research, Atlanta, GA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Zucker Hillside Hospital, Glen Oaks, NY OBJECTIVE: The investigational, positive allosteric modulator of ɣaminobutyric acid A (GABAA) receptors, brexanolone iv (BRX), was evaluated for efficacy and safety in women with postpartum depression (PPD) in 3 double-blind, placebo-controlled, randomized trials. ^[6] In this phase 3 double-blind placebo-controlled study, Goadsby et al. ^[7] Methods: Pts treated with EQW or placebo/non-GLP-1RA comparator drug (sitagliptin, metformin, pioglitazone, dapagliflozin, insulin) from 8 phase 3 double-blind or open-label 26/28-week studies were pooled and stratified by CKD stage. ^[8] Five were Phase 3 double-blind, placebo controlled RCTs. ^[9] METHODS This phase 3 double-blind study randomized patients with treatment-resistant depression (TRD) ≥65 years (1:1) to flexibly dosed esketamine nasal spray and new oral antidepressant (esketamine/antidepressant) or new oral antidepressant and placebo nasal spray (antidepressant/placebo). ^[10]